-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] Driven by factors such as the large demand for vaccines at home and abroad, and the booming production and sales of enterprises, the overall performance of the pharmaceutical industry in 2021 will be relatively stro.
Data released by the National Bureau of Statistics shows that in 2021, the operating income of China's pharmaceutical manufacturing industry will be 2,9285 billion yuan, a year-on-year increase of 21%; the total profit will be 6214 billion yuan, a year-on-year increase of 7
In 2021, the pharmaceutical circulation sector in the sub-sector will be promoted by the "dual channel" policy and centralized procurement, e.
, the industry market structure will be reshaped at an accelerated pace, and the market share of leading companies will increase significant.
According to industry statistics, as of now, 32 pharmaceutical distribution companies have disclosed their 2021 annual repor.
The overall performance of the companies is on the upward tre.
Among them, 16 companies have a revenue of over 10 billion yuan, and 4 companies have a revenue of more than 500 yu.
billi.
Sinopharm Holding Sinopharm Holding will achieve revenue of 521 billion yuan in 2021, a year-on-year increase of 12%; net profit attributable to the parent will reach 759 billion yuan, a year-on-year increase of 9
Among them, the medical device distribution segment achieved revenue of 108 billion yuan, a year-on-year increase of 21%; retail sales reached 29 billion yuan, an increase of 2
These two sectors mainly benefit from the implementation of centralized procurement and the "dual-channel" policy of retail pharmaci.
Among them, the company's retail business growth in 2021 is mainly due to the growth of the retail drug market and the network expansion of retail pharmaci.
It is reported that during the reporting period, Sinopharm Holding continued to improve the network layout of retail pharmacies, focusing on expanding the pharmacy stores with the qualifications of "Medical Insurance Coordination Pharmacy" and "Dual Channel", and striving to improve the professional pharmacy and marketing service capabilities of retail stor.
As of the end of 2021, Sinopharm Holding has accumulated more than 10,000 retail stores, an increase of 1,282 from the end of the previous ye.
The total number of "dual-channel" pharmacies has reached 403, covering 25 provinces across the country, and regional competitive advantages are constantly emergi.
In addition, in 2021, Sinopharm Holding's expense ratio is well controll.
Although the gross profit margin will drop by 38 percentage points to 45%, its sales and management expense ratio will reach 45%, and its financial expense ratio will be 6
Shanghai Pharmaceuticals Shanghai Pharmaceuticals will achieve revenue of 21824 billion yuan in 2021, a year-on-year increase of 14
Among them, the commercial revenue was 19726 billion yuan, a year-on-year increase of 142%, and the net profit attributable to the parent was 093 billion yuan, a year-on-year increase of 12
It is worth mentioning that the company will also achieve 3 billion yuan in sales revenue of imported vaccines in 202At the same time, the company accelerates the development of large varieties of traditional Chinese medici.
After the introduction of Yunnan Baiyao in 2021, Shanghai Pharma will deeply combine Yunnan Baiyao’s brand experience with the company’s rich pipeline and strong R&D capabilities, and cooperate to develop new and old varieties for the second time, aiming to manufacture more than 6 products8 Large varieties of 100 million yuan are expected to bring incremental income of 2 billion to 3 billion yu.
According to the 2021 annual report of Jointown, the company achieved a total operating income of 1241 billion yuan, a year-on-year increase of 14%; the net profit attributable to the parent was 45 billion, a year-on-year decrease of 2
Among them, the commercial distribution business achieved sales of 10751 billion yuan, a year-on-year increase of 170%, and gross profit of 403 billion yuan, a year-on-year increase of 9
As of the end of the reporting period, the business covered 12,000 public hospitals, 190,000 grassroots and private hospitals, 175,000 physical end customers such as chain and retail pharmacies, and 12 e-commerce platforms including .
com, Ali, Yihao, and Ley.
In 2021, the company's medical device segment and traditional Chinese medicine business segment achieved steady growth, recording sales of 2014 billion yuan and 239 billion yuan respectively, a year-on-year increase of 155% and 159% respective.
Among them, the medical device sector accounted for 162% of the company's overall sal.
Heavy Pharmaceutical Holdings Heavy Pharmaceutical Holdings will achieve operating income of 6521 billion yuan in 2021, a year-on-year increase of 326%; net profit attributable to the parent is 005 billion yuan, a year-on-year increase of 16
In 2021, with the optimization of the industrial structure and the acceleration of innovation and upgrading as the main line, the Group will actively cultivate new momentum for development and create new advantages for developme.
On the one hand, through the establishment of branches, mergers and acquisitions, e.
, it has newly entered the markets of Inner Mongolia, Zhejiang, and Shanghai, realizing the layout of 27 provinces and cities across the country, and sinking the regional network; The strategic business department will continue to enhance the supply chain extension service capabilities, improve the solution capabilities of pharmaceutical marketing business solutions, and focus on cooperation in contract sales projec.
In addition, it has steadily promoted the layout of its logistics network, newly built Ningxia logistics and put it into use, and made every effort to promote the construction of Tuzhu logistics (phase II), Gansu logistics, Sichuan logistics and Hubei logistics, and further improve the pharmaceutical logistics and distribution syst.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Data released by the National Bureau of Statistics shows that in 2021, the operating income of China's pharmaceutical manufacturing industry will be 2,9285 billion yuan, a year-on-year increase of 21%; the total profit will be 6214 billion yuan, a year-on-year increase of 7
In 2021, the pharmaceutical circulation sector in the sub-sector will be promoted by the "dual channel" policy and centralized procurement, e.
, the industry market structure will be reshaped at an accelerated pace, and the market share of leading companies will increase significant.
According to industry statistics, as of now, 32 pharmaceutical distribution companies have disclosed their 2021 annual repor.
The overall performance of the companies is on the upward tre.
Among them, 16 companies have a revenue of over 10 billion yuan, and 4 companies have a revenue of more than 500 yu.
billi.
Sinopharm Holding Sinopharm Holding will achieve revenue of 521 billion yuan in 2021, a year-on-year increase of 12%; net profit attributable to the parent will reach 759 billion yuan, a year-on-year increase of 9
Among them, the medical device distribution segment achieved revenue of 108 billion yuan, a year-on-year increase of 21%; retail sales reached 29 billion yuan, an increase of 2
These two sectors mainly benefit from the implementation of centralized procurement and the "dual-channel" policy of retail pharmaci.
Among them, the company's retail business growth in 2021 is mainly due to the growth of the retail drug market and the network expansion of retail pharmaci.
It is reported that during the reporting period, Sinopharm Holding continued to improve the network layout of retail pharmacies, focusing on expanding the pharmacy stores with the qualifications of "Medical Insurance Coordination Pharmacy" and "Dual Channel", and striving to improve the professional pharmacy and marketing service capabilities of retail stor.
As of the end of 2021, Sinopharm Holding has accumulated more than 10,000 retail stores, an increase of 1,282 from the end of the previous ye.
The total number of "dual-channel" pharmacies has reached 403, covering 25 provinces across the country, and regional competitive advantages are constantly emergi.
In addition, in 2021, Sinopharm Holding's expense ratio is well controll.
Although the gross profit margin will drop by 38 percentage points to 45%, its sales and management expense ratio will reach 45%, and its financial expense ratio will be 6
Shanghai Pharmaceuticals Shanghai Pharmaceuticals will achieve revenue of 21824 billion yuan in 2021, a year-on-year increase of 14
Among them, the commercial revenue was 19726 billion yuan, a year-on-year increase of 142%, and the net profit attributable to the parent was 093 billion yuan, a year-on-year increase of 12
It is worth mentioning that the company will also achieve 3 billion yuan in sales revenue of imported vaccines in 202At the same time, the company accelerates the development of large varieties of traditional Chinese medici.
After the introduction of Yunnan Baiyao in 2021, Shanghai Pharma will deeply combine Yunnan Baiyao’s brand experience with the company’s rich pipeline and strong R&D capabilities, and cooperate to develop new and old varieties for the second time, aiming to manufacture more than 6 products8 Large varieties of 100 million yuan are expected to bring incremental income of 2 billion to 3 billion yu.
According to the 2021 annual report of Jointown, the company achieved a total operating income of 1241 billion yuan, a year-on-year increase of 14%; the net profit attributable to the parent was 45 billion, a year-on-year decrease of 2
Among them, the commercial distribution business achieved sales of 10751 billion yuan, a year-on-year increase of 170%, and gross profit of 403 billion yuan, a year-on-year increase of 9
As of the end of the reporting period, the business covered 12,000 public hospitals, 190,000 grassroots and private hospitals, 175,000 physical end customers such as chain and retail pharmacies, and 12 e-commerce platforms including .
com, Ali, Yihao, and Ley.
In 2021, the company's medical device segment and traditional Chinese medicine business segment achieved steady growth, recording sales of 2014 billion yuan and 239 billion yuan respectively, a year-on-year increase of 155% and 159% respective.
Among them, the medical device sector accounted for 162% of the company's overall sal.
Heavy Pharmaceutical Holdings Heavy Pharmaceutical Holdings will achieve operating income of 6521 billion yuan in 2021, a year-on-year increase of 326%; net profit attributable to the parent is 005 billion yuan, a year-on-year increase of 16
In 2021, with the optimization of the industrial structure and the acceleration of innovation and upgrading as the main line, the Group will actively cultivate new momentum for development and create new advantages for developme.
On the one hand, through the establishment of branches, mergers and acquisitions, e.
, it has newly entered the markets of Inner Mongolia, Zhejiang, and Shanghai, realizing the layout of 27 provinces and cities across the country, and sinking the regional network; The strategic business department will continue to enhance the supply chain extension service capabilities, improve the solution capabilities of pharmaceutical marketing business solutions, and focus on cooperation in contract sales projec.
In addition, it has steadily promoted the layout of its logistics network, newly built Ningxia logistics and put it into use, and made every effort to promote the construction of Tuzhu logistics (phase II), Gansu logistics, Sichuan logistics and Hubei logistics, and further improve the pharmaceutical logistics and distribution syst.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
